Disease/Infection News

RSS

Partial success reported in the Phase 3 trial of HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases.

25 Sep 2009

Investigational vaccine shows modest potential for protecting against HIV infection

For the first time, scientists say an investigational vaccine has modest potential for protecting people against HIV infection, the Associated Press reports. "The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by ... 31 percent in the world's largest [HIV] vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok," the news service writes (Marchione/Casey, 9/24).

25 Sep 2009

Experimental HIV vaccine shows promise

An experimental HIV vaccine raises hope of reducing the risk of infection. Wall Street Journal/Associated Press reports: "For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible."

25 Sep 2009

NTMs: Rising cause of severe lung diseases

Nontuberculous mycobacteria (NTM) are environmental organisms found in both water and soil that can cause severe pulmonary (lung) disease in humans. Pulmonary NTM is on the rise in the United States, according to a large study of people hospitalized with the condition.

25 Sep 2009

Only 40% of parents will get their child vaccinated against H1N1?

The latest C.S. Mott Children's Hospital National Poll on Children's Health finds only 40 percent of parents indicate they will get their children vaccinated against H1N1 flu -- while 54 percent of parents indicate they will get their children vaccinated against seasonal flu. Among parents who do not plan to get their children vaccinated against H1N1 flu, 46 percent indicate they are not worried about their children getting H1N1 flu, while 20 percent believe H1N1 flu is not serious.

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Researchers find fungi effective for controlling malaria mosquitoes

In areas where malaria mosquitoes have become resistant to chemical pesticides, mosquito-killing fungi can be an effective tool. Fungal spores can effectively infect and kill malaria mosquitoes, even those that are resistant to pesticides.

25 Sep 2009

Clinton Global Initiative to raise awareness and funding for NTD control and elimination

At the Clinton Global Initiative today, the Inter-American Development Bank joined with the Global Network for Neglected Tropical Diseases to announce their commitment to mobilize $30 million from the public and private sectors to raise awareness and funding for NTD control and elimination in the Americas, supported by technical assistance from the Pan American Health Organization, regional office of the World Health Organization for the Americas.

24 Sep 2009

Mandell, Douglas, and Bennett's publication on infectious diseases released

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th Edition. Marking 30 years since its initial publication, it remains the most respected reference source of its kind, and maintains its relevance in the face of the emergence of newly recognized infectious diseases, including new strains of the swine (H1N1) and avian influenza viruses.

24 Sep 2009

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

Palmetto GBA-TrailBlazer Health cover Renessa treatment of female SUI

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC -- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia -- have agreed to cover the Renessa(R) treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

24 Sep 2009

Phase III efficacy trial of two AIDS vaccine candidates shows promise

The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial in Thailand. The prime-boost combination appeared to be about 31% effective at preventing infection with HIV.

24 Sep 2009

H1N1 slows growth in US industries and GDP

H1N1 influenza could slow growth in key industries and stall already-weak GDP growth in the third and fourth quarters of 2009, says a health economist in the University of Alabama at Birmingham (UAB) School of Business.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

Obama addresses U.N. General Assembly, calls for 'new era of engagement'

In his first U.N. General Assembly address, President Obama on Wednesday "called for 'a new era of engagement' ... with the world, pledging to work together with other countries while defending the interests of the United States," Reuters reports (9/23).

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

G20 preview: Obama to propose phasing out of fossil fuel subsidies; HIV/AIDS protesters take to streets in Pittsburgh

During the G20 summit opening Thursday in Pittsburgh, President Obama will propose countries around the world phase out government subsidies that promote the production and use of fossil fuels "that spew carbon dioxide, the chief greenhouse gas," the Associated Press reports (Borenstein, 9/23).

24 Sep 2009

Results of Phase III clinical trial of HIV vaccine released

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC(R)( )HIV and AIDSVAX(R) B/E( )lowered the rate of HIV infection by 31.2% compared with placebo.

24 Sep 2009

NIHR to fund patient panel for skin disease research

People who suffer from skin disease are being asked to help make research more effective by joining a new 'Patient Panel'.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009